✦ LIBER ✦

Immunotherapy with autologous dendritic cells in patients with hormone-refractory prostate carcinoma

✍ Scribed by R. Maier; R. de Giuli; J. Hering; R. von Moos; C. Böhme; H.-P. Schmid; T. Cerny; B. Ludewig; S. Gillessen

Book ID: 118624827
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 116 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80550-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dendritic cell-based multi-epitope immun

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

✍ Ying Waeckerle-Men; Edith Uetz-von Allmen; Markus Fopp; Roger von Moos; Christel 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 518 KB

Autologous Dendritic Cells Pulsed with P

Autologous Dendritic Cells Pulsed with Prostatic Acid Phosphatase (APC8015) for Patients with Hormone- Refractory Prostate Cancer with a Gleason Score ≤ 7

✍ Lee, David; Sartor, Oliver; Jain, Vinay K. 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 203 KB

Immunotherapy by autologous dendritic ce

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

✍ Mervat El Ansary, Sherif Mogawer, Samah Abd Elhamid, Sahr Alwakil, Fatma Aboelka 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 354 KB

Immunotherapy with autologous dendritic

Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors

✍ Aiko Suminoe; Akinobu Matsuzaki; Hiroyoshi Hattori; Yuhki Koga; Toshiro Hara 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

Suramin in combination with weekly epiru

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma

✍ Alfredo Falcone; Andrea Antonuzzo; Romano Danesi; Giacomo Allegrini; Lencioni Mo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## BACKGROUND. Suramin and epirubicin are both active agents in the treatment of patients with hormone-refractory advanced prostate carcinoma, with demonstrated antitumor synergism in vitro on human prostate carcinoma cells and different dose-limiting toxicities. The authors conducted this Phase I

582 Hematogenous tumour cell disseminati

582 Hematogenous tumour cell dissemination in patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy

✍ U. Schmidt; C. Linne; U. Bilkenroth; S. Feussel; K. Kraemer; M. Wirth; A. Meye 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 213 KB